KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer. The ...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of David Stewart as the new SVP and Site Head of KBI’s mammalian cGMP manufacturing facility in Durham, North...
KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D. Mowery as Chief Executive Officer (CEO).
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...
Through joint development with Bacchus Bio innovation, JSR will develop and produce raw materials for its key biomass products utilizing synthetic biology.
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP production, leading to pharmacokinetics/pharmacodynamic clinical trials
1 of 24
Receive JSR Life Sciences news on your RSS reader.
